期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

子宫颈癌调强放疗的研究进展 被引量：15

原文传递
导出
摘要 子宫颈癌是女性生殖系统常见的恶性肿瘤之一，放疗是子宫颈癌的主要治疗手段，近80％的子宫颈癌患者需要接受放疗[1]，但常规的全盆和（或）四野外照射靶区体积大、适形度差，直肠、膀胱、小肠、骨髓等正常组织受累较多，消化系统和泌尿系统等的急、慢性并发症发生率较高，严重影响了患者的生命质量。同时，由于正常组织较低的耐受剂量限制了靶区剂量的提升，使肿瘤局部控制率和患者生存率并未得到有效提高。调强放疗（intensity-modulated radiation therapy，IMRT）是近10多年来发展起来的1项放疗新技术，能实现照射野的形状与靶区形状一致，且照射野内诸点输出剂量率按要求分布，因此，IMRT可以在最大限度提高肿瘤照射剂量的同时尽量降低危及器官的受照体积及剂量，达到提高肿瘤局部控制率、减少并发症的目的。本文就近年来子宫颈癌IMRT的研究结果，及其用于临床的优势、存在的问题综述如下。
作者 李兴兰 盛修贵
机构地区 山东省肿瘤医院妇瘤科
出处 《中华妇产科杂志》 CAS CSCD 北大核心 2014年第9期710-712,共3页 Chinese Journal of Obstetrics and Gynecology
关键词 调强放疗 子宫颈癌 并发症发生率 局部控制率 恶性肿瘤 女性生殖系统 靶区体积 肿瘤照射剂量
分类号 R737.33 [医药卫生—肿瘤]
  • 相关文献

参考文献22

  • 1杜霄勐安菊生吴令英黄曼妮.子宫颈癌体外放疗新进展[J].中华妇产科杂志,2013,48(9):710-713. 被引量：11
  • 2肖锋,李云海,王洪林,陈洁,赵森,董海权,李永春.宫颈癌术后保护骨髓的调强放疗剂量学研究[J].中国癌症杂志,2013,23(3):200-206. 被引量：19
  • 3Du XL,Tao J,Sheng XG,et al.Intensity-modulated radiation therapy for advanced cervical cancer:a comparison of dosimetric and clinical outcomes with conventional radiotherapy[J].Gynecol Oncol,2012,125:151-157.
  • 4Zhang G,He F,Fu C,et al.Definitive extended field intensitymodulated radiotherapy and concurrent cisplatin chemosensitization in the treatment of Ⅰ B2-ⅢB cervical cancer[J].J Gynecol Oncol,2014,25:14-21.
  • 5Ring KL,Young JL,Dunlap NE,et al.Extended-field radiation therapy with whole pelvis radiotherapy and cisplatin chemosensitization in the treatment of Ⅰ B2-Ⅲ B cervical carcinoma:a retrospective review[J].Am J Obstet Gynecol,2009,201:109.el-6.
  • 6Du XL,Sheng XG,Jiang T,et al.Intensity-modulated radiation therapy versus para-aortic field radiotherapy to treat para-aortic lymph node metastasis in cervical cancer:prospective study[J].Croat Med J,2010,51:229-236.
  • 7柯桂好,黄啸,黄晓炜,刘素萍,吴小华.体外延伸野调强加腔内放疗联合化疗治疗子宫颈癌腹主动脉旁淋巴结转移的临床研究[J].中华妇产科杂志,2013,48(9):649-653. 被引量：24
  • 8Takeshita S,Kita T,Motoike Y,et al.Postoperative concurrent chemoradiotherapy for the high-risk uterine cervical cancer[J].J Obstet Gynaecol Res,2010,36:1009-1014.
  • 9I(g)dem S,Ercan T,Al(c)o G,et al.Dosimetric comparison of intensity modulated pelvic radiotherapy with 3D conformal radiotherapy in patients with gynecologic malignancies[J].Eur J Gynaecol Oncol,2009,30:547-551.
  • 10Mell LK,Tiryaki H,Ahn KH,et al.Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer[J].Int J Radiat Oncol Biol Phys,2008,71:1504-1510.

二级参考文献62

  • 1MELL L K, KOCHANSKI J D, ROESKE J C, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity- modulated pelvic radiotherapy [ J ] . Int J Radiat Oncol Biol Phys, 2006, 66(5): 1356-1365.
  • 2SMALL W, MELL L K, ANDERSON P, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer [ J ] . Int J Radiat Oncol Biol Phys, 2008, 71(2): 428-434.
  • 3TAYLOR A, ROCKALL A G, REZNEK R H, et al. Mapping pelvic lymph nodes: guidelines for delineation in intensity- modulated radiotherapy [ J ] . Int J Radiat 0ncol Biol Phys, 2005, 63(5): 1604-1612.
  • 4VALE C, TIERNRY J F, STEWART L A, et al. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trims [ J ] . J Clin Oncol, 2008, 26(35): 5802-5812.
  • 5LONG H J, BUNDY B N, GRENDYS E C, et al. Randomized phase Ⅲ trial of cisplatin with or without topotecan in carcinoma of the uterine cervix [ J ] . J Clin Oncol, 2005, 23(21): 4626-4633.
  • 6MOORE D H, BLESSING J A, MCQUELLON R P, et al. Phase Ⅲ study of cisplatin with or without paelitaxel in stage ⅣB, recurrent, or persistent squamous cell carcinoma of the cervix [ J ] . J Clin Oncol, 2004, 22 (15): 3113-3119.
  • 7BRIXEY C J, ROESKE J C, LUJAN A E, et al. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies [ J ] . Int J Radiat Oncol Biol Phys, 2002, 54(5): 1388-1396.
  • 8YANG B, ZHU L, CHENG H, et al. Dosimetric comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy in patients with gynecologic malignancies: a systematic review and meta-analysis [J] .Radiat Oneol, 2012, 7: 197.
  • 9KLOPPL A H, MOUGHAN J, PORTELANCE L, et al. Hematologic Toxicity on RTOG 0418: a phase II study of post- operative IMRT for gynecologic cancer [ J ] . Int J Radiat Oncol Biol Phys, 2010, 78(3): 258.
  • 10MELL L K, SCHOMAS D A, SALAMA J K, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and IMRT [ J ]. Int J Radiat Oncol Biol Phys, 2008, 70(5): 1431-1437.

共引文献48

同被引文献125

引证文献15

二级引证文献102

中华妇产科杂志
2014年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部